Aspen Investment Management Inc Grows Stock Holdings in Johnson & Johnson $JNJ

Posted by Stacy Sanders on May 21st, 2026

Aspen Investment Management Inc lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 89.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 18,170 shares of the company’s stock after purchasing an additional 8,600 shares during the period. Johnson & Johnson comprises about 1.1% of Aspen Investment Management Inc’s holdings, making the stock its 20th largest position. Aspen Investment Management Inc’s holdings in Johnson & Johnson were worth $3,760,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Plancorp LLC lifted its position in shares of Johnson & Johnson by 0.3% during the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock worth $3,288,000 after purchasing an additional 45 shares during the last quarter. WealthCollab LLC lifted its position in shares of Johnson & Johnson by 4.7% during the 4th quarter. WealthCollab LLC now owns 1,015 shares of the company’s stock worth $210,000 after purchasing an additional 46 shares during the last quarter. MMA Asset Management LLC lifted its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. MMA Asset Management LLC now owns 3,600 shares of the company’s stock worth $745,000 after purchasing an additional 46 shares during the last quarter. Vista Investment Partners II LLC lifted its position in shares of Johnson & Johnson by 1.2% during the 4th quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company’s stock worth $789,000 after purchasing an additional 47 shares during the last quarter. Finally, Campbell Deegan Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.6% during the 4th quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company’s stock worth $619,000 after purchasing an additional 48 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $229.22 on Thursday. The company’s fifty day moving average price is $234.43 and its 200 day moving average price is $222.90. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $551.78 billion, a P/E ratio of 26.50, a P/E/G ratio of 2.25 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period last year, the business earned $2.77 EPS. Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.12%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Argus lifted their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $265.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Daiwa Securities Group lifted their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Finally, Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target on the stock in a research note on Wednesday, May 13th. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

View Our Latest Research Report on Johnson & Johnson

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Analysts are pointing to J&J’s expanding pipeline, new drug approvals, and stronger cancer-drug sales as drivers of longer-term growth. J&J’s Pipeline Progress & New Drugs Promise Stronger Long-Term Growth
Positive Sentiment: New product momentum, including the global launch of the Shockwave C2 Aero coronary IVL catheter and encouraging clinical data in inflammatory bowel disease, is reinforcing optimism around JNJ’s medtech and immunology businesses. How Investors May Respond To Johnson & Johnson (JNJ) Advancing Immunology, Cardiology And Surgical Robotics Platforms
Positive Sentiment: J&J continues to be highlighted as a high-quality dividend stock, with articles emphasizing its defensive profile and reliability for income-focused investors. These 3 Dividend Stocks Are as Close to a Sure Thing as Investing Gets
Neutral Sentiment: Several roundup and conference articles kept JNJ in the spotlight, but they mostly reiterated existing themes rather than delivering a major new catalyst. Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson…

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.